CPG
NBIX icon

Cornerstone Planning Group’s Neurocrine Biosciences NBIX Stock Holding History

Cornerstone Planning Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.73K Hold
10
– – ﹤0.01% 1364
2026
Q1 		$1.35K Buy
10
+3
+43% +$398 ﹤0.01% 1379
2025
Q4 		$943 Sell
7
-1
-13% -$145 ﹤0.01% 1365
2025
Q3 		$358 Buy
8
+5
+167% +$677 ﹤0.01% 1558
2025
Q2 		$385 Hold
3
– – ﹤0.01% 1373
2025
Q1 		$310 Sell
3
-13
-81% -$1.65K ﹤0.01% 1403
2024
Q4 		$2.37K Buy
+16
New +$1.98K ﹤0.01% 749
2023
Q3 		– Sell
-13
Closed -$1.23K – 1277
2023
Q2 		$1.23K Buy
+13
New +$1.27K ﹤0.01% 1299
2022
Q4 		$1.43K Buy
+13
New +$1.52K ﹤0.01% 1280

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cornerstone Planning Group's NBIX Position: Q2 2026 in Review

Cornerstone Planning Group held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 10 shares worth $1.73K. The position accounts for ﹤0.01% of the portfolio, ranked #1364.

Cornerstone Planning Group first reported a position in NBIX in Q4 2022 and has held it in 9 quarters since. The position peaked at $2.37K in Q4 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Cornerstone Planning Group held 10 shares of Neurocrine Biosciences worth $1.73K as of Q2 2026.
  • Cornerstone Planning Group left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #1364 holding.
  • Cornerstone Planning Group first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 9 quarters since.
  • Cornerstone Planning Group's Neurocrine Biosciences position peaked at $2.37K in Q4 2024.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.